SecBot SecBot
8-K ·Filed Mar 31, 2026

OMER

OMEROS CORP
BULLISH
Impact 9/10
Horizonweeks Processed7mo ago SEC0001437749-26-010634
earnings-rerun-backfill
Actionable Insight ▲ Bullish

The massive beat and strong cash position support the commercial launch of YARTEMLEA and pipeline development. Monitor upcoming EMA decision on YARTEMLEA in mid-2026 and future milestone payments from Novo Nordisk as key catalysts.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$12.08
T+0 close · Mar 31, 2026 · via day close
Latest settled
−17.96%
T+60 · $9.91
Vs SPY
−31.34%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 1 $12.08entry
  2. T+1 · 8mo ago −9.77%α −9.85% · $10.90
  3. T+5 · 7mo ago −1.41%α −5.17% · $11.91
  4. T+20 · 7mo ago +20.53%α +10.81% · $14.56
  5. T+60 · 5mo ago −17.96%α −31.34% · $9.91
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Omeros reported a massive earnings beat for Q4 2025, driven by a $237.6M gain from the zaltenibart sale to Novo Nordisk and FDA approval of YARTEMLEA. The company turned profitable with GAAP net income of $86.5M ($1.22/share) versus a $31.4M loss in the prior year, while non-GAAP adjusted EPS hit $3.14, crushing consensus. Cash rose to $171.8M and debt was slashed by 47%.

Key Financial Metrics

EPS
$3.14
est −$0.55 · +670.9%
Revenue
$9.2M
est $1.7M · +441.2% · +441.2% YoY
Rating
strong beat

Key Facts

  • Net income for Q4 2025 was $86.5M ($1.22/share), compared to a net loss of $31.4M ($0.54/share) in Q4 2024
  • Non-GAAP adjusted net income was $222.5M ($3.14/share), a 670.9% beat vs. consensus of $-0.55
  • Recognized $237.6M in net proceeds from the sale of zaltenibart to Novo Nordisk
  • FDA approved YARTEMLEA for TA-TMA, with commercial launch underway in January 2026
  • Cash and short-term investments totaled $171.8M at year-end; debt reduced by $77.1M (47%) to $87.9M
  • OMIDRIA royalties were $9.2M in Q4 2025, down from $10.1M in Q4 2024

Financial Impact

$237.6M one-time gain from asset sale, $133.4M non-GAAP annual adjusted net income, $171.8M cash on hand

epsrevenuecashdebt

Risk Factors

  • Future earnings may decline as the $237.6M gain from the zaltenibart sale was non-recurring
  • OMIDRIA royalties continue to trend downward, falling to $9.2M in Q4 from $10.1M in the prior year

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001437749-26-010634
Document: omer20251116_8k.htm0001437749-26-010634
Document: 0001437749-26-010634-index-headers.html0001437749-26-010634
Document: 0001437749-26-010634-index.html0001437749-26-010634
Document: 0001437749-26-010634.txt0001437749-26-010634
8-K Data (Synthetic)0001437749-26-010634

US Market Status

Market Closed · Opens in 6h 36m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 21, 2026